Centre for Clinical Veterinary Medicine, Ludwig Maximilian University Munich, Veterinaerstr. 13, 80539 Munich, Germany.
Cytokine. 2014 Mar;66(1):54-9. doi: 10.1016/j.cyto.2013.12.001. Epub 2014 Jan 14.
Canine atopic dermatitis (CAD) is a common allergic skin disease that has been treated with subcutaneously administered interferons (IFN). Recombinant feline IFN-ω (rFeIFN-ω) was reported to be efficacious for CAD. Whether dogs develop neutralizing antibodies against rFeIFN-ω during long-term treatment and whether orally administered IFNs are efficacious in CAD is unknown. The aim of this study was to evaluate the potential development of antibodies against rFeIFN-ω in atopic dogs and to compare subcutaneous and oral IFN therapy. Twenty-six atopic dogs were randomly assigned to two groups. The first group (n=15) received eight subcutaneous injections of rFeIFN-ω (Virbagen® omega, Virbac, Carros, France) over four months, the second group (n=11) received rFeIFN-ω daily orally. Concurrent medication was permitted, except systemically acting glucocorticoids and cyclosporin, which had to be withdrawn at least two weeks prior to the study. Serum samples for antibody detection were collected before and after the study. On days 0, 60 and 120 skin lesions and pruritus were evaluated using a validated lesion score (Canine Atopic Dermatitis Extent and Severity Index=CADESI) and a validated pruritus score. Concurrent medications were recorded. For every visit a total score, consisting of CADESI, pruritus score and medication score was created. For antibody detection an indirect ELISA, using Virbagen® omega as antigen, was performed. Comparison of pruritus scores, CADESI and total scores between days 0 and 120 showed improvement in both groups, however, significant improvement could only be detected in the oral group with CADESI and total scores (61%, P=0.04 and 36%, P=0.02 respectively). Serum antibodies against rFeIFN-ω could not be detected in any of the dogs. In this study antibody production could not be demonstrated. It suggests better efficacy with oral IFN administration, which should be further verified in larger, randomized, controlled studies.
犬特应性皮炎（CAD）是一种常见的过敏性皮肤疾病，已通过皮下给予干扰素（IFN）进行治疗。据报道，重组猫 IFN-ω（rFeIFN-ω）对 CAD 有效。在长期治疗中，狗是否会产生针对 rFeIFN-ω 的中和抗体，以及口服 IFN 在 CAD 中的疗效如何，目前尚不清楚。本研究旨在评估特应性犬产生针对 rFeIFN-ω 的抗体的潜力，并比较皮下和口服 IFN 治疗。26 只特应性犬被随机分配到两组。第一组（n=15）在四个月内接受 8 次 rFeIFN-ω（Virbagen® omega，Virbac，Carros，法国）皮下注射，第二组（n=11）每天口服 rFeIFN-ω。允许同时使用药物，但全身作用的糖皮质激素和环孢素必须在研究前至少两周停用。在研究前后采集血清样本用于抗体检测。在第 0、60 和 120 天，使用经过验证的病变评分（犬特应性皮炎严重程度指数=CADESI）和经过验证的瘙痒评分评估皮肤病变和瘙痒。记录同时使用的药物。每次就诊时，根据 CADESI、瘙痒评分和药物评分创建总评分。用于抗体检测的间接 ELISA 使用 Virbagen® omega 作为抗原。与 0 天相比，两组的瘙痒评分、CADESI 和总评分均有所改善，但仅在口服组中可检测到 CADESI 和总评分的显著改善（61%，P=0.04 和 36%，P=0.02）。在任何一只狗的血清中都无法检测到针对 rFeIFN-ω 的抗体。在本研究中，未能检测到抗体产生。这表明口服 IFN 给药的疗效更好，这应在更大的、随机的、对照研究中进一步验证。
